Compare JAGU & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | JAGU | GRML |
|---|---|---|
| Founded | 2022 | N/A |
| Country | Canada | United States |
| Employees | 3 | 5 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.9M | 51.5M |
| IPO Year | N/A | 2022 |
| Metric | JAGU | GRML |
|---|---|---|
| Price | $1.93 | $0.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 83.8K | ★ 3.6M |
| Earning Date | 03-27-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.44 | $0.27 |
| 52 Week High | $3.60 | $0.55 |
| Indicator | JAGU | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 42.23 | 32.07 |
| Support Level | $1.52 | $0.28 |
| Resistance Level | $2.94 | $0.42 |
| Average True Range (ATR) | 0.24 | 0.04 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 43.92 | 4.74 |
Jaguar Uranium Corp is a uranium exploration and development company focused on uranium discoveries. The company is a junior miner engaged in uranium exploration. Its portfolio is comprised of two uranium exploration projects in Argentina and one uranium exploration project in Colombia. Its projects include the Berlin Project, the Laguna Project, and the Huemul Project. The company operates in one reportable segment which is the exploration and evaluation of mineral properties.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.